TG Therapeutics Inc (TGTX) Stock Price and News

Actionable insights straight to your inbox

TG Therapeutics Tumbles 40% on Partial Clinical Trial Hold

Is this a buying opportunity?

2 MIN READ
01.27.2022

TG Therapeutics Gets Breakthrough Therapy Designation for Lymphoma Treatment

Umbralisib is in Phase 3 trials in hematologic malignancies.

4 MIN READ
01.22.2019

Novimmune and Sobi Get FDA Approval for First Ever Primary HLH Therapy

First FDA-approved treatment for primary haemophagocytic lymphohistiocytosis (HLH). (Image: Novimmune)

4 MIN READ
11.20.2018

TG Therapeutics Shows Positive Final Phase 2 Data in Relapsing Multiple Sclerosis

Data presented at ECTRIMS, the world's largest MS conference

3 MIN READ
10.11.2018

Seven of the Best Investments You Could Have Made in 2014

Christmas comes but once a year, but a portfolio with huge returns is the gift that just keeps on giving. That’s why we’re taking the end of the year to look back at those investments

6 MIN READ
12.22.2014

Infinity Pharmaceuticals (INFI) Deal with AbbVie (ABBV) Boosts TG Therapeutics (TGTX) Stock

Stock in TG Therapeutics (TGTX) popped in Wednesday trading, seeing shares bounce 9.11%. Driving the gains appears to be the favorable deal secured by rival Infinity (INFI) with AbbVie (ABBV)

3 MIN READ
09.3.2014

TG Therapeutics Tumbles 40% on Partial Clinical Trial Hold

TG Therapeutics Gets Breakthrough Therapy Designation for Lymphoma Treatment

Novimmune and Sobi Get FDA Approval for First Ever Primary HLH Therapy

TG Therapeutics Shows Positive Final Phase 2 Data in Relapsing Multiple Sclerosis

Seven of the Best Investments You Could Have Made in 2014

Infinity Pharmaceuticals (INFI) Deal with AbbVie (ABBV) Boosts TG Therapeutics (TGTX) Stock

Sign up For our Newsletter

SITEMAP

Contact